@Rodrosb
Account based inSpain
About this account
- Account based in
- Spain
- Connected via
- Spain App Store
Account-level information from X, not a live location or the device used for a specific post.
MD, PhD. Oncólogo | Unidad de Cáncer de Mama y Ginecológico Hospital 12 de Octubre (Spain) | ESMO Young Oncologists Committee Chair
Joined May 2012
- Tweets2.6K
- Following694
- Followers4.6K
- Likes7.5K
Rodrigo Sánchez-Bayona retweeted
Attending #ESMO26? 📱Download the ESMO Events App to browse the programme, save your must-attend sessions and create your personalised agenda before you arrive.
A simple step to help you make the most of your congress experience from day one.
🔗 ow.ly/nbMX50ZZXgz
Rodrigo Sánchez-Bayona retweeted
New at #ESMO26: the ESMO Principles for Humanising Scientific Reporting.
Designed to strengthen the communication of oncology research while maintaining scientific rigour and patient relevance.
🔗 ow.ly/WzeJ50ZZIqH
Rodrigo Sánchez-Bayona retweeted
📰 @ESMO_Open publica el paper 'Germline pharmacogenetic variants associated with trastuzumab deruxtecan-induced interstitial lung disease in advanced breast cancer: PROCURE project', un estudio multicéntrico presentado por el Dr. @Rodrosb en la Plenaria de #SEOM26
🔗 sciencedirect.com/science/ar…
🧬 New study from the PROCURE project in @ESMO_Open @myESMO explores the genetic basis of TDxD–induced ILD in breast cancer.
📊 290 patients
• ILD incidence: 11.4%
• Strongest association mapped near HLA-F
• Additional signals SLCO1B1, CYP3A4
kwnsfk27.r.eu-west-1.awstrac…
Rodrigo Sánchez-Bayona retweeted
📌 2nd International Multidisciplinary Consensus on the Integration of Radiation Therapy with New Systemic Treatments @ESTRO_RT
🧬PARPi and Immunotherapy in Breast
Cancer: Clinical Evidence, Patient Selection and Therapeutic Indications
@Rodrosb 🇪🇸
#FlorenceConsensus26 @OncoAlert #OncoAlertAF
Rodrigo Sánchez-Bayona retweeted
Superb @Rodrosb brings the systemic therapy perspective.
PARP inhibitors and immunotherapy in #BreastCancer: which patients, which indications, and how strong is the evidence? Key discussion on combining these agents with RT!
@OncoAlert @KaidarOrit
Rodrigo Sánchez-Bayona retweeted
Orit Kaidar Person and Rodrigo Sanchez Bayona dance showing radiobiological rationale and clinical evidence for combination of PARPi and ICIs with #radiotherapy in #BreastCancer
#FlorenceConsensus26 #OncoAlert @OncoAlert @ESTRO_RT @myESMO
Rodrigo Sánchez-Bayona retweeted
🔴 Plenaria #SEOM26
📰 Identifican genes relacionados con el riesgo de neumonitis por trastuzumab-deruxtecán en pacientes con cáncer de mama
🩺 Dr. @Rodrosb, secretario científico de @_SEOM y oncólogo médico del @H12Octubre
seom.org/images/NP_Plenaria_…
Rodrigo Sánchez-Bayona retweeted
Outcomes of elacestrant in pts with ER+ HER2, ESR1m metastatic breast cancer who received prior ET & CDK4/6 inhibitor in a RW setting in @ESMO_Open.Durable benefit of elacestrant with 8.2 months of mTTNT after 1 to 2 lines of ET+CDK4/6i. esmoopen.com/article/S2059-7…
Rodrigo Sánchez-Bayona retweeted
Managing HR+/HER2- Early Breast Cancer in the Genomic Era - Rodrigo Sanchez Bayona (@Rodrosb)
oncodaily.com/science/rodrig…
Rodrigo Sánchez-Bayona retweeted
We would like to inform you that your post has been published on OncoDaily. Thank you for sharing.
oncodaily.com/science/rodrig…
New paper on the management of HR+/HER2- early breast cancer in the genomic era! 🧬
Here are the real-world outcomes on how intermediate-risk (i-ROR) PAM50 patients fit into the new landscape of adjuvant CDK4/6 inhibitors:
rdcu.be/ftLOF
In total, nearly half (48.6%) of these intermediate-risk patients met the criteria for at least one adjuvant iCDK4/6. This highlights the need to refine risk stratification and carefully consider adjuvant systemic therapies, like iCDK4/6, even when genomic scores are intermediate
And this work was made during a Clinical Unit Visit Fellowship of Dr Maria Illia (from Argentina) at our Institution @H12Octubre thanks to @myESMO
@PTarantinoMD @PabloMando @matteolambe @E_de_Azambuja @GuiNaderMarta @TeresaSAmaral
Rodrigo Sánchez-Bayona retweeted
Delighted to share that we officially kicked off the @JSMO_official working group dedicated to career development for fellows and early-career oncologists! The launch would not have been possible without the immense help of @NazliDizman from @ASCOTECAG and @Rodrosb from @myESMO!
日本臨床腫瘍学会( @JSMO_official)の専攻医・若手キャリアワーキンググループが始動しました！メンバー募集を開始しましたので、腫瘍内科若手医師でどんな角度でも良いので学会を通したキャリア支援活動に興味ある方は以下より参加希望フォームにアクセスください！
jsmo.or.jp/post-11665/
Do not miss this great discussion about resilience and sustainable career in Oncology 👇🏻
With wonderful people @DrVilmaPBarcia @Ioanna_Nixon thanks so much for inviting me!
@Rodrosb it was wonderful having you at @OpenDoors_Onc, thank you so much for coming!!
🎧Tune in for a brilliant conversation on resilience and a sustainable career. @Ioanna_Nixon
🔗m.youtube.com/watch?si=PH_P9…
🔗 open.spotify.com/episode/12p…
Rodrigo Sánchez-Bayona retweeted
🎙️ #Episode22 is now live! We’re joined by Dr. @Rodrosb Chair of @myesmo YOC, breast cancer specialist and medical oncologist at @HUniv12Octubre. We discuss #resilience and breast cancer research. Hosted by @Ioanna_Nixon and @DrVilmaPBarcia.
🔗youtube.com/watch?si=PH_P9Z1…
@oncodaily